(Q38930844)

7 September 2017

title

Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2. (English)

1 reference

7 September 2017

main subject

neoplastic invasiveness

1 reference

Chun-Xiong Zhao

1

1 reference

7 September 2017

Chun-Li Luo

series ordinal

2

1 reference

7 September 2017

Xiao-Hou Wu

series ordinal

3

1 reference

7 September 2017

publication date

7 December 2014

1 reference

7 September 2017

1 reference

7 September 2017

volume

32

1 reference

7 September 2017

issue

1

1 reference

7 September 2017

page(s)

419

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-014-0419-4

7 September 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Role and regulation of prolyl hydroxylase domain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Turn me on: regulating HIF transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

The impact of O2 availability on human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

BRG1 and BRM chromatin-remodeling complexes regulate the hypoxia response by acting as coactivators for a subset of hypoxia-inducible transcription factor target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

HIF-1 and HIF-2: working alone or together in hypoxia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Cyclooxygenase-2 and the inflammogenesis of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

The cell-cell adhesion molecule E-cadherin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

The basics of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

The LIM protein AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

EMT: a new vision of hypoxia promoting cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

EMT as the ultimate survival mechanism of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Hypoxia-inducible factors and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0419-4

Targeting castration-induced tumour hypoxia enhances the acute effects of castration therapy in a rat prostate cancer model

21 January 2018

1 reference

12 December 2020

Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids

1 reference

12 December 2020

CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer

1 reference

12 December 2020

Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha

1 reference

12 December 2020

Epidemiologic aspects of renal cell cancer

1 reference

12 December 2020

Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity

1 reference

12 December 2020

Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines

1 reference

12 December 2020

Role of CBP in regulating HIF-1-mediated activation of transcription.

1 reference

12 December 2020

Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo

1 reference

12 December 2020

Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice

1 reference

12 December 2020

Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations

1 reference

12 December 2020

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry

1 reference

12 December 2020

10.1007/S12032-014-0419-4

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1033112270

0 references

1 reference